Hematologic side effects of PEG interferon and ribavirin. Management with growth factors.
Keeffe
Emmet B
EB
Stanford University Medical Center, Palo Alto, CA
Kowdley
Kris V
KV
D000998:Antiviral Agents / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D006133:Growth Substances / Q000627:therapeutic use*; D006402:Hematologic Diseases / Q000139:chemically induced / Q000188:drug therapy*; D019698:Hepatitis C, Chronic / Q000188:drug therapy; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D011092:Polyethylene Glycols / Q000009:adverse effects*; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects*; D014481:United States / Q000453:epidemiology
D000998:Antiviral Agents; D006133:Growth Substances; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a